LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors.

MUNICH--(BUSINESS WIRE)--Tubulis today announced the appointment of Björn Hock, PhD, as Chief Development Officer (CDO) to further strengthen its leadership team with a seasoned drug development ...

The interest in the potential of antibody-drug conjugates (ADC) continues to grow among some of pharma’s biggest players. Bristol Myers Squibb (BMS) announced Thursday morning that it has entered into ...

LAUSANNE, Switzerland, June 15, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the election of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 30 ...

USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...

Samsung Biologics signed a partnership deal with LegoChem Biosciences focused on the development and production of antibody-drug conjugates (ADCs). Although financial details of the deal weren’t ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Tubulis announced the successful closing of a €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors ...